Doylestown PA, USA and Oxford, UK - 27 October 2007 – EUSA Pharma Inc (‘EUSA’), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Adrian Haigh as Vice President Global Marketing.
Mr Haigh will also join the company’s Executive Committee. Adrian Haigh brings to EUSA considerable international and commercial expertise. Having gained 25 years’ experience in the pharmaceutical and biotechnology industries, Mr Haigh joins EUSA from Amgen where he led the international oncology franchise and held joint P&L responsibility for sales of $1.5 billion. He previously held senior commercial and marketing positions at SmithKline Beecham, Schering Plough, Organon and Novo Nordisk, and has headed affiliate companies in a number of European countries. Mr Haigh holds a degree in Economic History and a diploma in Marketing.
“I am delighted to welcome Adrian to the growing team at EUSA,” said Bryan Morton, Chief Executive of EUSA Pharma. “As we continue to expand our transatlantic infrastructure, Adrian’s combination of international experience and leadership skills will prove invaluable. Having completed three significant acquisitions in the first 18 months since EUSA was founded, we have a strong and growing portfolio of products in Europe and North America, which will benefit greatly from Adrian’s commercial and marketing expertise.” Commenting on his appointment, Adrian Haigh, EUSA Pharma’s Vice President Global Marketing, said, “It is rare to have the opportunity to join a company with EUSA’s ambition and impressive track record, so I am thrilled to become part of a team that has made such great progress during its short history. I share the company’s vision of building a major transatlantic business built on a unique combination of specialist medical and geographic focus, and look forward to playing a full role in helping make that a reality.”
EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on inlicensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has six products on the market, including the antibiotic surgical implant Collatamp® G, Erwinase® and Kidrolase® for the treatment of acute lymphoblastic leukemia, and Rapydan™, a rapid-onset anesthetic patch for which EUSA expects to receive Europe-wide approval in 2007. EUSA also has several products in late-stage development, notably Collatamp® G topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx® bupivacaine implant for local post-surgical pain control.
Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $225 million and completed a number of significant transactions, including the acquisitions of Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US and Canada, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to maintain a strong focus on acquisitions and in-licensing within its specialist medical and geographic areas, in line with its ambition to create a $1 billion company by the first half of the next decade.
For more information please visit www.eusapharma.com
EUSA Pharma UK
Bryan Morton, Chief Executive +44 (0) 1865 784 255
Julia Phillips / Emma Thompson +44 (0) 20 7831 3113
For more information:
Last updated on: 27/08/2010